JPH06509228A - 改善されたワクチン - Google Patents

改善されたワクチン

Info

Publication number
JPH06509228A
JPH06509228A JP5502485A JP50248593A JPH06509228A JP H06509228 A JPH06509228 A JP H06509228A JP 5502485 A JP5502485 A JP 5502485A JP 50248593 A JP50248593 A JP 50248593A JP H06509228 A JPH06509228 A JP H06509228A
Authority
JP
Japan
Prior art keywords
protein
domain
virus
rabies
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5502485A
Other languages
English (en)
Japanese (ja)
Inventor
ウォーカー，ピーター・ジョン
プレフォード，クリストフ・ジーン
Original Assignee
コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション filed Critical コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション
Publication of JPH06509228A publication Critical patent/JPH06509228A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP5502485A 1991-07-17 1992-07-17 改善されたワクチン Pending JPH06509228A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPK725891 1991-07-17
PCT/AU1992/000363 WO1993001833A1 (en) 1991-07-17 1992-07-17 Improved vaccine
AU7258 1995-12-21

Publications (1)

Publication Number Publication Date
JPH06509228A true JPH06509228A (ja) 1994-10-20

Family

ID=3775548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5502485A Pending JPH06509228A (ja) 1991-07-17 1992-07-17 改善されたワクチン

Country Status (5)

Country Link
EP (1) EP0595970A4 (de)
JP (1) JPH06509228A (de)
CA (1) CA2113572A1 (de)
NZ (1) NZ243611A (de)
WO (1) WO1993001833A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519336A (ja) * 2011-06-13 2014-08-14 メディカゴ インコーポレイテッド 植物中での狂犬病ウイルス様粒子の生成

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA937164B (en) * 1992-09-28 1994-05-23 Commw Scient Ind Res Org Delivery system
US6818209B1 (en) 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
DE69941049D1 (de) * 1998-05-22 2009-08-13 Oxford Biomedica Ltd Retrovirales verabreichungssystem
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
DE60037263T2 (de) * 2000-12-29 2008-10-09 Evotec Ag Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
WO2008124636A1 (en) 2007-04-04 2008-10-16 Weatherford/Lamb, Inc. Apparatus and methods of milling a restricted casing shoe
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
CN102533680B (zh) * 2011-06-24 2014-03-26 武汉生物制品研究所有限责任公司 狂犬病毒病毒样颗粒及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601378B2 (en) * 1985-10-04 1990-09-13 Pharmacia & Upjohn Company Pseudorabies virus protein
US5037742A (en) * 1986-07-18 1991-08-06 E. I. Du Pont De Nemours And Company Pseudorabies virus recombinants and their use in the production of proteins
NZ230425A (en) * 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
ES2026826A6 (es) * 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados.
ES2026827A6 (es) * 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
GB9107631D0 (en) * 1991-04-10 1991-05-29 British Bio Technology Proteinaceous particles
CA2086831C (en) * 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519336A (ja) * 2011-06-13 2014-08-14 メディカゴ インコーポレイテッド 植物中での狂犬病ウイルス様粒子の生成

Also Published As

Publication number Publication date
EP0595970A1 (de) 1994-05-11
WO1993001833A1 (en) 1993-02-04
CA2113572A1 (en) 1993-02-04
NZ243611A (en) 1993-12-23
EP0595970A4 (de) 1995-05-31

Similar Documents

Publication Publication Date Title
JP3816126B2 (ja) 組換え伝染性非セグメント化陰性鎖ｒｎａウイルス
EP1644037B1 (de) Funktionale influenza-virus-ähnliche teilchen (vlps)
EP0835132B1 (de) Rekombinante temperaturempfindliche influenza-virus mutanten
HU229101B1 (en) Dna transfection system for the generation of infectious influenza virus
JP2009529861A (ja) 鳥インフルエンザウイルスのｈ５ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス
JP5432703B2 (ja) 組み換えモノネガウイルス目ウイルスベクター
Li et al. A recombinant canine distemper virus expressing a modified rabies virus glycoprotein induces immune responses in mice
JPH06509228A (ja) 改善されたワクチン
JPH01501357A (ja) ヒト呼吸器系ウイルス用ワクチン
CN101155826B (zh) 作为疫苗的复制缺陷型rna病毒
BARRERA et al. Persistence of vesicular stomatitis virus New Jersey RNA in convalescent hamsters
EP3865180A1 (de) Lebende rekombinante masernviren, die coronavirus-antigene exprimieren, verwendung davon zur erzeugung von immunität gegen coronaviren
IL143149A (en) Stable mutants of rabies virus and live vaccines prepared from them
JP2002507408A (ja) 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異
US20110027308A1 (en) Compositions and methods for preventing influenza infection in canines, felines and equines
Ong et al. Cloning and expression of the HN gene from the velogenic viscerotropic Newcastle disease virus strain AF2240 in Sf9 insect cells
AU2366592A (en) Improved vaccine
RU2435857C2 (ru) ВЕКТОРЫ НА ОСНОВЕ РЕКОМБИНАНТНЫХ ВИРУСОВ ОТРЯДА Mononegavirales
CN118749028A (zh) 重组减毒rsv活疫苗株及其产生方法
AU2011218606B2 (en) Functional influenza virus-like particles (VLPS)
CN117618550A (zh) 流感病毒、新型冠状病毒、呼吸道合胞病毒三联疫苗及其制备方法
Tompkins et al. Efficacy of Parainfluenza Virus 5 Mutants
HK1091118B (en) Functional influenza virus-like particles (vlps)
MXPA04012878A (es) Caracterizacion y aislamiento de cepas variantes del virus del sindrome del ojo azul (soa) y aislamiento del gen hn de las mismas.